TME PHARM.CONF.IPO EO 1- Net Assets
TME PHARM.CONF.IPO EO 1- net assets. Based on the latest financial reports, TME PHARM.CONF.IPO EO 1- (0N6A) has net assets worth €-1.58 Million EUR (≈ $-1.85 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.14 Million ≈ $2.50 Million USD) and total liabilities (€3.72 Million ≈ $4.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore TME PHARM.CONF.IPO EO 1- net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.58 Million |
| % of Total Assets | -73.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 34.79 |
Net Assets of TME PHARM.CONF.IPO EO 1- (2021–2025)
Net assets of TME PHARM.CONF.IPO EO 1- from 2021 to 2025. This chart illustrates how TME PHARM.CONF.IPO EO 1-'s net assets have evolved over time, based on quarterly financial data. See TME PHARM.CONF.IPO EO 1- balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for TME PHARM.CONF.IPO EO 1- (2021–2025)
The table below shows the annual net assets of TME PHARM.CONF.IPO EO 1- from 2021 to 2025. For live market cap and overall valuation, see market value of TME PHARM.CONF.IPO EO 1-.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-1.58 Million ≈ $-1.85 Million |
-197.83% |
| 2024-12-31 | €1.61 Million ≈ $1.89 Million |
+648.98% |
| 2023-12-31 | €-294.00K ≈ $-343.72K |
+76.89% |
| 2022-12-31 | €-1.27 Million ≈ $-1.49 Million |
-128.25% |
| 2021-12-31 | €4.50 Million ≈ $5.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to TME PHARM.CONF.IPO EO 1-'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3087400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
TME PHARM.CONF.IPO EO 1- Net Assets Breakdown (December 2025)
TME PHARM.CONF.IPO EO 1- net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €201.80 Million | % |
| Total Equity | €-1.58 Million | 100.00% |
TME PHARM.CONF.IPO EO 1- Competitors by Market Cap
The table below lists competitors of TME PHARM.CONF.IPO EO 1- ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Panda Financial Holding Corp Ltd
SHG:600599
|
$10.45 Million |
|
Pertama Digital Berhad
KLSE:8532
|
$10.45 Million |
|
Argenica Therapeutics Ltd
AU:AGN
|
$10.45 Million |
|
Tractial S.A.
PA:ALTRA
|
$10.46 Million |
|
Txcom SA
PA:ALTXC
|
$10.44 Million |
|
Centrex Ltd
AU:CXM
|
$10.44 Million |
|
mVISE AG
XETRA:C1V
|
$10.43 Million |
|
BIOEXTRAX AB
F:85X0
|
$10.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TME PHARM.CONF.IPO EO 1-'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,614,000 to -1,579,000, a change of -3,193,000 (-197.8%).
- Net loss of 3,285,000 reduced equity.
- New share issuances of 8,000 increased equity.
- Other factors increased equity by 84,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.29 Million | -208.04% |
| Share Issuances | €8.00K | +0.51% |
| Other Changes | €84.00K | +5.32% |
| Total Change | €- | -197.83% |
Book Value vs Market Value Analysis
This analysis compares TME PHARM.CONF.IPO EO 1-'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.10 | €0.13 | x |
| 2022-12-31 | €-0.50 | €0.13 | x |
| 2023-12-31 | €-0.01 | €0.13 | x |
| 2024-12-31 | €0.02 | €0.13 | x |
| 2025-12-31 | €-0.02 | €0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TME PHARM.CONF.IPO EO 1- utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-134.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -320.09% | 0.00% | 0.00x | 2.16x | €-14.90 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-15.00 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-6.71 Million |
| 2024 | -354.52% | 0.00% | 0.00x | 2.11x | €-5.88 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-3.13 Million |
Industry Comparison
This section compares TME PHARM.CONF.IPO EO 1-'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $364,908,577
- Average return on equity (ROE) among peers: -60.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TME PHARM.CONF.IPO EO 1- (0N6A) | €-1.58 Million | -320.09% | N/A | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-338.57 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-2.33 Million | 0.00% | 0.00x | $960.84K |
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indicatio… Read more